StreetAlpha
Arrowhead Pharmaceuticals, Inc. · SEC Form 4

ARWR Insider Trading

From SEC Form 437 trades in 2 yearsUpdated Nov 19, 2026

Every open market buy and sale of Arrowhead Pharmaceuticals, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $37.3M sold.

← ARWR stock page

Insiders are only selling
Bought, 12 months$00 buys · 0 insiders
Sold, 12 months$37.3M19 sales · 10 insiders
Net−$37.3Mbought minus sold
Planned sales45%of sold value, 10b5-1 plans

Buying and selling by month

open market, last 12 months
2025-12: sold $26.6MDec2026-01: sold $6.5MJanFeb2026-03: sold $642KMar2026-04: sold $1.7MApr2026-05: sold $228KMayJunJul2026-08: sold $1.2MAugSepOctNov
Bought (up)Sold (down)
AI Pro · insider alerts

Get an alert when ARWR insiders trade

We read every Form 4 the moment the SEC posts it and tell you when an ARWR officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.

Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.

Every ARWR insider trade

2 years · newest first
InsiderTypePriceHeld afterFiled
Aug 18, 2026Adeoye Y OlukotunDirectorSale2,000$86.96$174K31,600Aug 20Form 4
Aug 18, 2026Michael S PerryDirectorSale11,600$87.30$1M111,459Aug 20Form 4
May 12, 2026Hongbo LuDirectorSale plan2,970$76.88$228K52,012May 14Form 4
Apr 23, 2026James C HamiltonChief Medical OfficerSale plan10,000$75.00$750K226,958Apr 24Form 4
Apr 22, 2026Daniel Joseph ApelCFOSale plan13,095$71.35$934K162,905Apr 24Form 4
Mar 5, 2026James C HamiltonChief Medical OfficerSale plan10,000$64.19$642K236,958Mar 9Form 4
Jan 5, 2026Patrick O'BrienCOOSale plan49,493$63.11$3.1M474,908Jan 5Form 4
Jan 5, 2026James C HamiltonChief Medical OfficerSale plan40,164$63.11$2.5M171,958Jan 5Form 4
Jan 2, 2026Christopher Richard AnzaloneCEOSale plan13,187$66.10$872K3,792,739Jan 5Form 4
Dec 29, 2025Christopher Richard AnzaloneCEOSale plan51,726$69.13$3.6M3,805,926Dec 30Form 4
Dec 26, 2025Mauro FerrariDirectorSale plan7,530$70.00$527K69,053Dec 30Form 4
Dec 22, 2025Christopher Richard AnzaloneCEOSale plan26,031$68.04$1.8M3,805,926Dec 23Form 4
Dec 19, 2025Adeoye Y OlukotunDirectorSale plan10,000$67.66$677K33,600Dec 23Form 4
Dec 19, 2025William D. WaddillDirectorSale plan8,367$67.65$566K56,563Dec 23Form 4
Dec 19, 2025Victoria VakienerDirectorSale plan10,040$67.68$679K35,723Dec 23Form 4
🔒 22 more trades. Create a free account or sign in to see them all.

ARWR insider trading FAQ

Are ARWR insiders buying or selling?

Insiders are only selling over the last 12 months. 0 insiders bought $0 of ARWR on the open market in 0 trades, and 10 sold $37.3M in 19 trades, 45% of that under pre-arranged trading plans.

When did an ARWR insider last buy shares?

There has been no open market insider purchase of ARWR in the last two years.

When did an ARWR insider last sell shares?

Adeoye Y Olukotun (Director) sold 2,000 shares for $174K on Aug 18, 2026.

What is a Form 4?

Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.

Why do insider sales matter less than buys?

Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.

From SEC Form 4 filings · Not investment advice